David Ricks, Eli Lilly CEO (AP Photo/Carolyn Kaster)

IRA side ef­fect: Phar­ma com­pa­nies will in­creas­ing­ly skip Medicare al­to­geth­er, Lil­ly CEO says

As the Cen­ters for Medicare and Med­ic­aid Ser­vices races to fi­nal­ize guid­ance on how it will ne­go­ti­ate — or dic­tate, de­pend­ing on if you ask a phar­ma ex­ec — the prices of the costli­est med­i­cines in the US, phar­ma ex­ecs are warn­ing of un­want­ed reper­cus­sions.

Eli Lil­ly CEO David Ricks told JP Mor­gan an­a­lysts on Wednes­day that for some new drugs, com­pa­nies might just skip out on seek­ing en­try in­to the Medicare pro­gram al­to­geth­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA